Physician profile
George Kannarkat
NPI 1992856579
$1,275.53
in general payments reported to CMS, 2019-2025
18 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $20.52 · 2023: $89.82 · 2024: $724 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533 · Consulting Fee: $525 · Travel and Lodging: $56.28 · Education: $16.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.69 |
| Consulting Fee | $525.00 |
| Travel and Lodging | $56.28 |
| Education | $16.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $525.00 | 2024 | Calquence |
| Comsort, INC | $100.00 | 2019 | |
| Array Biopharma INC | $75.31 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Pfizer INC. | $67.41 | 2024-2025 | |
| Daiichi Sankyo INC. | $61.58 | 2025 | Datroway, Enhertu |
| Medtronic, INC. | $56.28 | 2023 | Percept PC Brainsense |
| Abbvie INC. | $54.46 | 2025 | |
| Janssen Biotech, INC. | $52.87 | 2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $50.25 | 2024 | |
| Puma Biotechnology, INC. | $39.94 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $36.98 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $30.30 | 2024 | |
| Celgene Corporation | $27.07 | 2024 | Reblozyl |
| Seagen INC. | $24.58 | 2019 | |
| Caris Mpi, INC. | $21.19 | 2025 | Mi Cancer Seek |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $20.27 | 2023 | Jakafi |
| Merck Sharp & Dohme LLC | $18.77 | 2025 | Welireg, Keytruda |
| Amgen INC. | $13.27 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kannarkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.